 SAN DIEGO, Jan. 29, 2021 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation Nasdaq: ADMP, a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today the pricing of its previously announced underwritten public offering of 40,540,540 shares of its common stock at a public offering price of 1.11 per share, resulting in gross proceeds of approximately 45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the company. All shares of common stock to be sold in the public offering are being sold by Adamis. 